834PInterim results of a phase Ib study of niraparib plus androgen receptor-targeted therapy in men with metastatic castration-resistant prostate cancer. (23rd October 2018) - Saad, F; Chi, K N; Shore, N; Graff, J N; Posadas, E M; Freeman, S; Tryon, J; Trudel, G C; de Jong, J; Meltzer, J; Zhao, X; Tran, N; et al.